替雷利珠单抗联合新辅助化疗治疗局部晚期宫颈癌的疗效分析OA

Objective:To retrospectively review the efficacy and safety of neoadjuvant chemotherapy(NACT)plus PD-1 inhibitor tislelizumab immunotherapy in patients with locally advanced cervical cancer(LACC).Methods:Clinical data of 52 patients with locally advanced cervical cancer admitted to the First Medical Center of Chinese PLA General Hospital from Au-gust 2022 to August 2024 were collected.The efficacy and safety of the patients were retrospec-tively reviewed after neoadjuvant chemo-immunotherapy.Result:Among 52 patients,11(21.2%)cases were complete response,29(55.8%)cases were partial response,8(15.4%)cases were stable disease and 4(7.7%)cases were progressive disease.The objective response rate was 77%and the disease control rate was 92.3%.38 patients completed surgery,and a pathological complete response was observed in 8(21.2%)patients.The medium follow-up of the cohort was 16 months,the 2-year progression-free survival was 94.4%and the 2-year over-all survival rate was 82.9%.Treatment-related adverse events were reported in 44 patients(84.6%).Grade1～2 TRAEs occurred in 63.5%of the patients.Grade 3～4 TRAEs oc-curred in 30.8%of the patients.No treatment-related deaths occurred.The treatment was well-tolerated among patients.Conclusions:Neoadjuvant chemotherapy(NACT)plus tislelizumab immunotherapy showed promising antitumour activity and good safety.